+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
All Ages
All Genders
ID07219576

Phase 1b Study of Retifanlimab with Ruxolitinib for Patients with Metastatic Renal Cell Carcinoma or Non-Small Cell Lung Cancer Resistant to Prior PD-1PD-L1 Therapy

Led by University of California, San Diego · Updated on 2026-01-13

40

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the combination of two drugs, ruxolitinib and retifanlimab, in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma who have progressed after prior immunotherapy. The goal is to find the highest safe dose of ruxolitinib when used with retifanlimab and to evaluate how well this combination works. This study addresses an important need for new treatments for patients whose cancers have become resistant to previous immunotherapies. The trial uses a dose escalation design to test different doses of ruxolitinib taken orally twice daily alongside fixed-dose retifanlimab given intravenously every four weeks. Participants will be assigned to dose levels starting at 15 mg and 20 mg of ruxolitinib, with possible reductions to 10 mg or 5 mg if necessary. After determining the recommended phase 2 dose, an expansion group will receive treatment at that dose level. Participants will keep a diary to record their ruxolitinib use at home and visit the clinic for retifanlimab infusions every four weeks. Regular checkups and tests will monitor their health and response to treatment. The main outcome measured is the recommended phase 2 dose after 28 days. The study is sponsored by the University of California, San Diego and plans to continue until December 2029.

CONDITIONS

Brief Title

Retifanlimab and Ruxolitinib In Solid Malignancies

Research Team

R

Rana McKay, MD

A

Alexandrea Cronin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here